Naděžda Machková

1.2k total citations
48 papers, 808 citations indexed

About

Naděžda Machková is a scholar working on Genetics, Immunology and Epidemiology. According to data from OpenAlex, Naděžda Machková has authored 48 papers receiving a total of 808 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Genetics, 24 papers in Immunology and 19 papers in Epidemiology. Recurrent topics in Naděžda Machková's work include Inflammatory Bowel Disease (32 papers), Microscopic Colitis (17 papers) and Biosimilars and Bioanalytical Methods (11 papers). Naděžda Machková is often cited by papers focused on Inflammatory Bowel Disease (32 papers), Microscopic Colitis (17 papers) and Biosimilars and Bioanalytical Methods (11 papers). Naděžda Machková collaborates with scholars based in Czechia, Italy and Germany. Naděžda Machková's co-authors include Milan Lukáš, Martin Bortlík, Dana Ďuricová, Karin Malíčková, Luděk Hrdlička, Veronika Hrubá, Martin Lukáš, Arnošt Komárek, Katarína Mitrová and Patrik Španěl and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and The American Journal of Gastroenterology.

In The Last Decade

Naděžda Machková

43 papers receiving 803 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Naděžda Machková Czechia	13	438	418	309	214	182	48	808
Iwona Wrobel Canada	13	444 1.0×	454 1.1×	211 0.7×	21 0.1×	309 1.7×	21	1.2k
Anne‐Emmanuelle Berger France	12	212 0.5×	355 0.8×	280 0.9×	83 0.4×	78 0.4×	41	547
Margien L. Seinen Netherlands	15	55 0.1×	419 1.0×	210 0.7×	421 2.0×	84 0.5×	23	674
Naja Becher Denmark	16	107 0.2×	125 0.3×	193 0.6×	136 0.6×	74 0.4×	34	600
Bruce C. Gilliland United States	10	185 0.4×	141 0.3×	140 0.5×	70 0.3×	66 0.4×	20	742
Jennifer Domm United States	16	104 0.2×	43 0.1×	100 0.3×	107 0.5×	45 0.2×	37	531
Ana Maria Arruda Lana Brazil	13	165 0.4×	49 0.1×	240 0.8×	35 0.2×	88 0.5×	23	696
Demetrios Petropoulos United States	12	205 0.5×	129 0.3×	160 0.5×	73 0.3×	38 0.2×	44	781
Liliana Aparecida Lucci De Angelo Andrade Brazil	15	77 0.2×	48 0.1×	343 1.1×	96 0.4×	288 1.6×	53	782
Zohreh Nademi United Kingdom	13	292 0.7×	107 0.3×	172 0.6×	66 0.3×	97 0.5×	32	549

Countries citing papers authored by Naděžda Machková

Since Specialization

Citations

This map shows the geographic impact of Naděžda Machková's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naděžda Machková with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naděžda Machková more than expected).

Fields of papers citing papers by Naděžda Machková

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naděžda Machková. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naděžda Machková. The network helps show where Naděžda Machková may publish in the future.

Co-authorship network of co-authors of Naděžda Machková

This figure shows the co-authorship network connecting the top 25 collaborators of Naděžda Machková. A scholar is included among the top collaborators of Naděžda Machková based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naděžda Machková. Naděžda Machková is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ďuricová, Dana, Martin Kolář, Naděžda Machková, et al.. (2023). Subcutaneous Infliximab in Refractory Crohn’s Disease Patients: A Possible Biobetter?. Crohn s & Colitis 360. 5(4). otad040–otad040. 10 indexed citations

Lukáš, Milan, Veronika Hrubá, Naděžda Machková, et al.. (2023). Switch from biosimilar infliximab CT-P13 to biosimilar infliximab SB-2 in the long-term maintenance therapy in IBD patients – prospective observational study. 77(4). 336–341. 1 indexed citations

Kolář, Martin, et al.. (2023). EFFICIENCY OF DUAL THERAPY WITH VEDOLIZUMAB AND TOFACITINIB IN REFRACTORY ULCERATIVE COLITIS PATIENTS – SINGLE CENTRE EXPERIENCE. Inflammatory Bowel Diseases. 29(Supplement_1). S78–S78.

Ďuricová, Dana, Martin Lukáš, Naděžda Machková, et al.. (2022). Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients. Journal of Crohn s and Colitis. 16(9). 1347–1353. 8 indexed citations

Kucharzik, Torsten, Rune Wilkens, Maria Antonietta D’Agostino, et al.. (2021). S902 Intestinal Ultrasound Response and Transmural Remission After 48 Weeks of Treatment With Ustekinumab in Crohn’s Disease: STARDUST Trial Substudy Results by Line of Treatment and by Location. The American Journal of Gastroenterology. 116(1). S426–S426. 2 indexed citations

Kucharzik, Torsten, Rune Wilkens, Giovanni Maconi, et al.. (2020). Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn’s disease: Week 16 interim analysis of the STARDUST trial substudy. Zeitschrift für Gastroenterologie. 58. 1 indexed citations

Malíčková, Karin, Martin Bortlík, Dana Ďuricová, et al.. (2020). Telemedicine and inflammatory bowel disease – results of the IBD Assistant pilot project. 74(1). 18–27. 1 indexed citations

Malíčková, Karin, Martin Bortlík, Dana Ďuricová, et al.. (2020). P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn s and Colitis. 14(Supplement_1). S352–S353. 2 indexed citations

Kucharzik, Torsten, Rune Wilkens, Giovanni Maconi, et al.. (2020). DOP10 Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn’s disease: Week 16 interim analysis of the STARDUST trial substudy. Journal of Crohn s and Colitis. 14(Supplement_1). S046–S048. 10 indexed citations

10.

Kolář, Martin, Dana Ďuricová, Martin Bortlík, et al.. (2019). Vedolizumab vs. ustekinumab as second-line therapy in Crohn’s disease in clinical practice. 73(1). 25–31. 3 indexed citations

11.

Ďuricová, Dana, Eva Dvořáková, Ondřej Hradský, et al.. (2018). Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation. Inflammatory Bowel Diseases. 25(4). 789–796. 61 indexed citations

12.

Ďuricová, Dana, et al.. (2018). P614 Pregnancy outcomes in women with IBD treated with biosimilar infliximab. Journal of Crohn s and Colitis. 12(supplement_1). S419–S420. 7 indexed citations

13.

Bortlík, Martin, Naděžda Machková, Veronika Hrubá, et al.. (2018). Efficacy of ustekinumab in a patient refractory to other biological treatment. 72(1). 47–49.

14.

Ďuricová, Dana, Martin Bortlík, Veronika Hrubá, et al.. (2017). Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre. Digestive Diseases. 35(1-2). 91–100. 41 indexed citations

15.

Dryahina, Kseniya, David Smith, Martin Bortlík, et al.. (2017). Pentane and other volatile organic compounds, including carboxylic acids, in the exhaled breath of patients with Crohn’s disease and ulcerative colitis. Journal of Breath Research. 12(1). 16002–16002. 46 indexed citations

16.

Bortlík, Martin, Naděžda Machková, Dana Ďuricová, et al.. (2013). Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study. Scandinavian Journal of Gastroenterology. 48(8). 951–958. 53 indexed citations

17.

Hrdlička, Luděk, Kseniya Dryahina, Patrik Španěl, et al.. (2012). Tu1248 Noninvasive Quantification of Volatile Metabolites in Breath: A Potential Indicator of Inflammatory Bowel Diseases Activity. Gastroenterology. 142(5). S–784. 2 indexed citations

18.

Bortlík, Martin, Dana Ďuricová, Karin Malíčková, et al.. (2012). Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. Journal of Crohn s and Colitis. 7(9). 736–743. 202 indexed citations

19.

Bortlík, Martin, et al.. (2012). P360 Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease: A single cohort study. Journal of Crohn s and Colitis. 6. S153–S153. 5 indexed citations

20.

Bortlík, Martin, et al.. (2011). Endoscopic Balloon Dilatation of Anastomotic Strictures in Patients With Crohn's Disease: Effect of Immediate Endoscopic Success and Biological Therapy. Gastroenterology. 140(5). S–281. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact